List of Wound Healing Companies with Phase 3 Active Clinical Trial - 16

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Applied Biologics is a fully-integrated life sciences company providing research, product development, manufacturing and distribution of medical technologies. Since 2010, Applied Biologics has been dedicated to providing innovative biologic solutions to deliver optimal patient outcomes. The entire Applied Biologics team is dedicated to each other and the company's success. The executive team, medical advisory board, scientific advisory board, researchers, product development team, manufacturing technicians, distribution team, sales representatives, support team, reimbursement department and administrative staff are professionals and leaders in their fields. Together, we continue to strive for excellence and being a leader in delivering biological solutions to treat a growing list of medical indications.

AVITA Medical (NASDAQ: RCEL, ASX:AVH) is a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient's own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a Biosynthetic Wound Matrix, in the United States.

B. Braun is one of the world's leading medical technology companies. With over 65,000 employees, the family-owned company is a true partner, developing smart solutions and setting standards to drive advancements in health care. In 2022, the B. Braun Group generated sales of € 8.5 billion. You want to protect and improve the health of people around the world? Then you need a work environment that makes it easy for you to give your best. We bring together people in a collaborative culture. We encourage them to be open-minded, learn from each other and create new solutions together. In a time of rapid technological change, we constantly strive to enhance the solutions we provide. This is why we promote innovative ways of thinking and accountability. Imprint: https://www.bbraun.com/en/imprint.html Privacy Policy: https://www.bbraun.com/en/privacy-policy.html

At Convatec, #ForeverCaring is our promise to patients & healthcare providers, as we deliver pioneering trusted medical solutions to improve the lives we touch. #ForeverConvatec

Direct Biologics is a market-leading innovator in regenerative medicine.

At Elutia we’re pioneering the future of patient care. Our proprietary drug-eluting biomaterial platforms stand at the forefront of medical innovation.

Embody, Inc. is a commercial-stage company pioneering the next generation in collagen-based tendon and ligament healing for the fast-growing sports medicine market. Founded in 2014, the company is developing unique biomaterials with an initial focus on orthopedic applications including Achilles, rotator cuff and knee ligament repair.

Femasys is a biomedical company focused on transforming women's healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc®, a first and only non-surgical product for permanent birth control and FemaSeed™, a first and only directed sperm delivery product for infertility treatment. Femasys' FemVue® product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician's office setting.

With 81 patents and patents pending, Kane Biotech is Kane Biotech is THE Biofilm Company. Creating smarter ways to fight bacteria, Kane is leading the advancement of technologies and products that break up biofilms and destroy bacteria. Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol "KNBIF".

KiOmed Pharma is a biotechnology company based in Belgium that focuses on developing, manufacturing, and distributing chitosan-based medical devices. The company, a spinout from KitoZyme, utilizes exclusive natural chitosan chemistry to create solutions for high-impact medical conditions, particularly in osteoarthritis, dermatology, and ophthalmology. Headquartered in Herstal, Liège, KiOmed Pharma emphasizes therapeutic innovations through its proprietary KiOmedine® technology platform. One of its key products is KioMedine(vs)one, a single-injection soft implant designed to relieve pain and improve mobility in knee osteoarthritis patients. The company is also developing additional products targeting joint health, skin aging, and eye-related disorders. KiOmed Pharma maintains a commitment to biocompatibility and safety by using non-animal-derived chitosan in its formulations. In April 2024, KiOmed Pharma formed a strategic alliance with Aptissen to globally commercialize KioMedine(vs)one, enhancing patient access to its treatments while generating revenue through royalties and milestone payments. Under the leadership of CEO Houtaï Choumane, the company aims to create long-term value and improve patient outcomes in chronic diseases.

MolecuLight Inc. a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection of wounds containing elevated bacterial burden > 10^4 CFU/g (when used with clinical signs and symptoms) and for digital wound measurement #moleculight

Primex ehf is an icelandic marine biotech company who is a global leader in the manufacture and supply of chitosans and chitin derivatives. The traceability of ChitoClear TM starts by registering the catching area of the shrimp in the North Atlantic Ocean.

Progenitec is a healthcare company that facilitates faster healing of chronic wounds through accurate and fast diagnosis.

A forward-thinking, medical technology company dedicated to developing life-saving products and therapies that encourage healing, reduce complications of tissue damage and inflammation, prevent infection by drug-resistant bacteria and remove the biofilms in which they thrive. We use the best of nature to solve important, real-time problems.

Vomaris Innovations, Inc. is a medical device company based in Tempe, Arizona, that focuses on bioelectric technology for infection control and wound healing. Founded in 2004, the company operates globally, with its products registered in nine countries and over one million wounds treated using its technology. The company's patented V.Dox™ Technology utilizes moisture-activated microcell batteries embedded in a substrate. This technology generates a wireless electric field that mimics the body's natural healing process, targeting bacterial biofilms and reducing infection risk. Vomaris offers products such as the Procellera® Antimicrobial Wound Dressing, which is validated in numerous peer-reviewed publications, and the PowerHeal™ Antibacterial Bioelectric Bandages, available over-the-counter for superficial wounds. Their solutions are applicable in various medical fields, including chronic and acute wound care, surgical incisions, and veterinary medicine.